Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation.
Whether the decrease of portal venous inflow and portal pressure induced by somatostatin is related to the effects of somatostatin in inhibiting the secretion of glucagon and other vasodilatory peptides that are increased in portal hypertension was investigated in the current study. Splanchnic vascular resistance and splanchnic blood flow were determined using radioactive microspheres in rats with portal hypertension caused by partial portal vein ligation. Somatostatin infusion significantly decreased portal pressure (from 13.1 +/- 1.9 to 12.1 +/- 2.2 mm Hg; P less than 0.05). This was associated with a significant decrease in portal venous inflow caused by splanchnic vasoconstriction, as evidenced by increased splanchnic vascular resistance, and with a marked suppression of glucagon secretion. The simultaneous infusion of somatostatin and glucagon (2.8 ng/min, a dose that prevented any decrease in circulating glucagon levels) abolished all the hemodynamic effects of somatostatin. This effect seems to be specific because no hemodynamic changes were noted in portal hypertensive rats receiving only the glucagon infusion.
Pizcueta
M P
MP
Liver Unit, Hospital Clínic i Provincial, University of Barcelona, Spain.
García-Pagán
J C
JC
Fernández
M
M
Casamitjana
R
R
Bosch
J
J
Rodés
J
J
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005934:Glucagon / Q000097:blood / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects*; D006975:Hypertension, Portal / Q000097:blood / Q000503:physiopathology*; D008297:Male; D011168:Portal System / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012039:Regional Blood Flow / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology*; D013152:Splanchnic Circulation / Q000187:drug effects*; D014664:Vasodilation / Q000502:physiology
D013004:Somatostatin; D005934:Glucagon